研究单位：[1]Haihe Biopharma Co., Ltd.[2]Norton Cancer Institute,Louisville,Kentucky,United States,40233[3]The Oncology Institute of Hope & Innovation,Louisville,Kentucky,United States,40233[4]Anhui Province Hospital,Hefei,Anhui,China,230000[5]The Chest Hospital of Anhui Province,Hefei,Anhui,China,230000[6]Beijing Cancer Hospital,Beijing,Beijing,China,100000[7]Beijing Cancer Hospita,Beijing,Beijing,China,100000[8]Peking Union Medical College Hospital,Beijing,Beijing,China,100000[9]Union Medical College Hospital Affiliated to Fujian Medical University,Fuzhou,Fujian,China,350000[10]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510000[11]Cancer Hospital Affiliated to Guangxi Medical University,Nanning,Guangxi,China,530000[12]Hainan Cancer Hospital,Haikou,Hainan,China,570000[13]Cancer Hospital Affiliated to Harbin Medical University,Ha'erbin,Heilongjiang,China,150000[14]Henan Province Cancer Hospital,Zhengzhou,Henan,China,450000[15]Hubei Cancer Hospital,Wuhan,Hubei,China,430000[16]Wuhan Union Hospital,Wuhan,Hubei,China,430000[17]Xiangya Hospital Central South University,Changsha,Hunan,China,410000[18]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210000[19]Jiangsu Province People's Hospital,Nanjing,Jiangsu,China,210000[20]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330000[21]First Hospital of Jilin University,Changchun,Jilin,China,130000[22]Liaoning Cancer Hospital,Shenyang,Liaoning,China,110000[23]Affiliated Hospital of Hebei University,Baoding,Shandong,China,071000[24]Shandong University Qilu Hospital,Jinan,Shandong,China,250000[25]Changhai Hospital,Shanghai,Shanghai,China,200000[26]Fudan university Shanghai cancer center,Shanghai,Shanghai,China,200000[27]The Chest Hospital of Shanghai,Shanghai,Shanghai,China,200000[28]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610000[29]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300000[30]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300000[31]The First Affiliated Hospital，College of of Medicine, Zhejiang University,Hangzhou,Zhejiang,China,310000[32]Zhejiang Province Cancer Hospital,Hangzhou,Zhejiang,China,310000[33]Hunan Province Cancer Hospital,Changsha,China,410000[34]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China,450000[35]Ehime University Hospital,Ehime,Japan[36]Kyushu University Hospital,Fukuoka,Japan[37]Kanagawa Cancer Center,Kanagawa,Japan[38]Niigata Cancer Center Hospital,Niigata,Japan[39]Kindai University Hospital,Osaka,Japan[40]Osaka International Cancer Institute,Osaka,Japan[41]Hokkaido University Hospital,Sapporo,Japan[42]Shizuoka Cancer Center,Shizuoka,Japan[43]National Cancer Center Hospital East,Tokyo,Japan[44]National Cancer center,Tokyo,Japan[45]Tottori University Hospital,Tottori,Japan
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
